125 related articles for article (PubMed ID: 19239456)
21. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
24. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
25. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden.
Andrén O; Fall K; Andersson SO; Rubin MA; Bismar TA; Karlsson M; Johansson JE; Mucci LA
Br J Cancer; 2007 Sep; 97(6):730-4. PubMed ID: 17726465
[TBL] [Abstract][Full Text] [Related]
26. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
27. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
[TBL] [Abstract][Full Text] [Related]
29. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
30. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of elongation factor-1α is significantly correlated with poor prognosis of human prostate cancer.
Liu H; Ding J; Chen F; Fan B; Gao N; Yang Z; Qi L
Scand J Urol Nephrol; 2010 Nov; 44(5):277-83. PubMed ID: 20545466
[TBL] [Abstract][Full Text] [Related]
32. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
D'Amico AV; Halabi S; Vollmer R; Loffredo M; McMahon E; Sanford B; Archer L; Vogelzang NJ; Small EJ; Kantoff PW;
Urology; 2008 May; 71(5):933-7. PubMed ID: 18291508
[TBL] [Abstract][Full Text] [Related]
33. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.
Jeetle SS; Fisher G; Yang ZH; Stankiewicz E; Møller H; Cooper CS; Cuzick J; Berney DM;
Virchows Arch; 2012 Aug; 461(2):103-7. PubMed ID: 22767265
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
38. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
[TBL] [Abstract][Full Text] [Related]
40. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
